<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976456</url>
  </required_header>
  <id_info>
    <org_study_id>65 plus</org_study_id>
    <secondary_id>ML21896</secondary_id>
    <nct_id>NCT00976456</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer</brief_title>
  <acronym>65plus</acronym>
  <official_title>Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Wolfgang Schuette</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Martha-Maria Krankenhaus Halle-Dölau gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, open, randomized (parallel) and comparative phase III.

      Eligible patients will receive bevacizumab + chemotherapy for a minimum of 4 cycles followed
      by bevacizumab (+ pemetrexed, if appropriate) maintenance therapy until disease progression.

      Arm A: Bevacizumab + pemetrexed

      Arm B: Bevacizumab + pemetrexed + carboplatin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:

        -  Proof of non-inferior efficacy of a monochemotherapy regimen of pemetrexed plus
           bevacizumab versus a combination chemotherapy regimen of pemetrexed-carboplatin plus
           bevacizumab in elderly patients(&gt; 65 years) as first-line treatment of advanced
           metastatic or recurrent non-squamous NSCLC by progression free survival

      Secondary:

        -  To assess the efficacy of bevacizumab as measured by overall response rate and overall
           survival.

        -  To assess the safety of bevacizumab in combination with pemetrexed and pemetrexed and
           carboplatin.

        -  To assess quality of life by EORTC questionnaire QLQ-C30 and its lung cancer module
           LC-13

        -  To assess activity of daily life (iADL) in relation to ECOG performance status prior to
           study treatment

        -  To assess patient`s outcome and treatment delivery in relation to the Charlson
           comorbidity score and the Simplified Comorbidity Score
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>42 months</time_frame>
    <description>Progression free survival (defined as the number of days from the day of the first treatment until day of death (from any cause) or progression, whichever occurs earlier, or until the day of the last response assessment, if no progression or death (from any cause) is observed during the study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>42 months</time_frame>
    <description>Overall survival (defined as the number of days from the day of first treatment to death (from any cause), or until the last day if we know that the patient is alive).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Non-squamous Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab + Pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab + Pemetrexed + Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab + Pemetrexed</intervention_name>
    <description>Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks</description>
    <arm_group_label>Bevacizumab + Pemetrexed</arm_group_label>
    <other_name>Avastin®</other_name>
    <other_name>ALIMTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab + Pemetrexed + Carboplatin</intervention_name>
    <description>Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks</description>
    <arm_group_label>Bevacizumab + Pemetrexed + Carboplatin</arm_group_label>
    <other_name>Avastin®</other_name>
    <other_name>ALIMTA®</other_name>
    <other_name>Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IIIb and IV NSCLC, excluded squamous cell NSCLC

          -  Age ≥ 65 years

          -  ECOG 0-2

        Exclusion Criteria:

          -  Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a
             predominant squamous component

          -  History of haemoptysis

          -  Evidence of tumour invading major blood vessels on imaging

          -  Radiotherapy within 28 days prior to enrolment

          -  Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory
             agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day
             period for long-acting agents, such as piroxicam)

          -  Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral
             or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.
             Prophylactic use of anticoagulants is allowed

          -  Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months
             before enrolment), myocardial infarction (≤6 months before enrolment), unstable
             angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the
             study and might interfere with regularity of the study treatment, or not controlled by
             medication

          -  Non-healing wound, active peptic ulcer or bone fracture

          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 months of enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Schuette, PhD MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Krankenhaus Martha-Maria Halle-Doelau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>February 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2016</results_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martha-Maria Krankenhaus Halle-Dölau gGmbH</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Wolfgang Schuette</investigator_full_name>
    <investigator_title>PhD MD</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>elderly</keyword>
  <keyword>non-squamous</keyword>
  <keyword>Elderly patients at least 65 years old</keyword>
  <keyword>first line therapy</keyword>
  <keyword>non-squamous non-small cell lung cancer stage IIIb or IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Pemetrexed</title>
          <description>Bevacizumab + Pemetrexed
Bevacizumab + Pemetrexed: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Bevacizumab + Pemetrexed + Carboplatin</title>
          <description>Bevacizumab + Pemetrexed + Carboplatin
Bevacizumab + Pemetrexed + Carboplatin: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>screening failure, unknown</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>271 patients were enrolled and randomized, due to Screening failure and subject withdrawn consent the intent-to-treat (ITT) population comprised 253 evaluable patients (BP n=119; BPC n=134).</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Pemetrexed</title>
          <description>Bevacizumab + Pemetrexed
Bevacizumab + Pemetrexed: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Bevacizumab + Pemetrexed + Carboplatin</title>
          <description>Bevacizumab + Pemetrexed + Carboplatin
Bevacizumab + Pemetrexed + Carboplatin: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="253"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="B2" value="72.0" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="B3" value="71.5" lower_limit="65" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival (defined as the number of days from the day of the first treatment until day of death (from any cause) or progression, whichever occurs earlier, or until the day of the last response assessment, if no progression or death (from any cause) is observed during the study).</description>
        <time_frame>42 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Pemetrexed</title>
            <description>Bevacizumab + Pemetrexed
Bevacizumab + Pemetrexed: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Pemetrexed + Carboplatin</title>
            <description>Bevacizumab + Pemetrexed + Carboplatin
Bevacizumab + Pemetrexed + Carboplatin: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival (defined as the number of days from the day of the first treatment until day of death (from any cause) or progression, whichever occurs earlier, or until the day of the last response assessment, if no progression or death (from any cause) is observed during the study).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.3" upper_limit="6.0"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.8" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The estimation was that in the pemetrexed-carboplatin plus bevacizumab Arm the median PFS will be 5.5 months. A median PFS of 4 months (5.5 – 27%) had been regarded non-inferior. Assuming the accrual period of 24 months and the whole study duration of 42 months, 246 patients had to be recruited. According to the fact, that the required statistical power of 80% will be reached by occurrence of altogether 227 events, the final analysis was done at this time point.</non_inferiority_desc>
            <p_value>0.0583</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.290</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.989</ci_lower_limit>
            <ci_upper_limit>1.682</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (defined as the number of days from the day of first treatment to death (from any cause), or until the last day if we know that the patient is alive).</description>
        <time_frame>42 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Pemetrexed</title>
            <description>Bevacizumab + Pemetrexed
Bevacizumab + Pemetrexed: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Pemetrexed + Carboplatin</title>
            <description>Bevacizumab + Pemetrexed + Carboplatin
Bevacizumab + Pemetrexed + Carboplatin: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (defined as the number of days from the day of first treatment to death (from any cause), or until the last day if we know that the patient is alive).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="8.6" upper_limit="14.4"/>
                    <measurement group_id="O2" value="14.4" lower_limit="11.7" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The estimation was that in the pemetrexed-carboplatin plus bevacizumab Arm the median PFS will be 5.5 months. A median PFS of 4 months (5.5 – 27%) had been regarded non-inferior. Assuming the accrual period of 24 months and the whole study duration of 42 months, 246 patients had to be recruited. According to the fact, that the required statistical power of 80% will be reached by occurrence of altogether 227 events, the final analysis was done at this time Point.</non_inferiority_desc>
            <p_value>0.3869</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.794</ci_lower_limit>
            <ci_upper_limit>1.499</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Pemetrexed</title>
          <description>Bevacizumab + Pemetrexed
Bevacizumab + Pemetrexed: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Bevacizumab + Pemetrexed + Carboplatin</title>
          <description>Bevacizumab + Pemetrexed + Carboplatin
Bevacizumab + Pemetrexed + Carboplatin: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="83" subjects_affected="61" subjects_at_risk="119"/>
                <counts group_id="E2" events="146" subjects_affected="97" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Wolfgang Schuette</name_or_title>
      <organization>Krankenhaus Martha-Maria Halle-Doelau gGmbH</organization>
      <phone>+49 345 5591440</phone>
      <email>wolfgang.schuette@martha-maria.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

